Moderna clears key FDA flu panel hurdle, shares trade around one-year high

Moderna’s experimental mRNA-based influenza vaccine received unanimous backing from an FDA advisory panel, adding to a recent recovery that has pushed the NASDAQ-listed biotech’s shares toward a one-year high.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:40.

Moderna Inc. (US60770K1034) has secured unanimous support from a U.S. Food and Drug Administration advisory committee for its experimental mRNA-based influenza vaccine candidate. The NASDAQ-listed biotech is trading close to a one-year high, with the FDA panel vote seen as a fresh sector-relevant milestone according to recent market coverage from MarketBeat and other outlets.MarketBeat news overview on Moderna

What the FDA panel backed

The FDA advisory committee recently voted unanimously that the benefit-risk profile of Moderna’s investigational mRNA influenza vaccine is favorable, a key step toward potential approval in the U.S. as summarized in several financial news reports.Yahoo Finance report on the FDA vote The panel’s recommendation is not binding but typically carries significant weight in subsequent FDA decisions.

The candidate, which targets multiple influenza strains using mRNA technology similar to Moderna’s COVID-19 vaccine, is designed to generate immune responses against seasonal flu with an adaptable platform. According to coverage of the advisory meeting, committee members discussed immunogenicity data and safety outcomes before issuing their unanimous vote, which analysts note reduces regulatory uncertainty in this indication.MSN summary of the panel backing

How Moderna shares and peers compare

Moderna shares trade on the NASDAQ under the ticker MRNA and recently closed at about 59.75 US dollars, a level cited in several market data services as near a one-year high for the stock.MarketBeat quote and one-year high data for MRNA Extended trading indications show prices modestly below that close, consistent with a biotech sector that has seen mixed performance across vaccine-focused names.

In the vaccine and immunology peer group, Moderna competes with Pfizer, BioNTech and other developers of respiratory virus vaccines, with the prospective influenza product adding another revenue stream beyond COVID-19. Sector comparisons from analyst aggregators highlight that Moderna’s valuation multiple reflects both the pipeline optionality and the volatility typical for mid-large cap biotech names, with price histories showing marked swings around regulatory and clinical events.MarketWatch market data and sector comparison for Moderna

The product behind the stock

Moderna’s most prominent commercial product remains its Spikevax COVID-19 mRNA vaccine, which delivered substantial revenue during the pandemic years and continues to contribute via updated formulations for circulating variants. The company’s broader pipeline includes respiratory virus candidates such as RSV and the newly backed influenza vaccine, as well as programs in oncology and rare diseases leveraging the same mRNA platform to instruct cells to produce specific proteins.

Where the Moderna shares trade today

The Moderna shares (US60770K1034) trade on the NASDAQ at 59.75 US dollars as of 2026-06-25, 16:00 Eastern Time, according to recent market data.

Key data on the Moderna shares

• Company: Moderna Inc.
• ISIN: US60770K1034
• WKN: A2N9D9
• Ticker: MRNA
• Trading venue: NASDAQ
• Price (as of 2026-06-25, 16:00): 59.75 USD
• Market cap: around 23 billion USD (as of late June 2026)
• Sector / industry: Biotechnology / Pharmaceuticals
• Index membership: NASDAQ-100
• Next earnings date: not officially scheduled

Disclaimer: This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.